NeuroDerm
Rehovot
About NeuroDerm
NeuroDerm is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders that will make a clinically meaningful difference in patients’ lives. NeuroDerm’s technology enables new routes of administration for existing drugs that overcome their current deficiencies and achieve enhanced clinical efficacy.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 101 – 250
- Estimated revenue: Less than $1M
- Total funding: $170.5M
- Funding stage: M&A
- Last round: Post-IPO Equity (Dec 2016)
- Ticker: nasdaq:NDRM
- Website: neuroderm.com
- Phone: +972 8-946-2729
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/neuroderm-164254 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.